KPF
AUPH icon

K2 Principal Fund’s Aurinia Pharmaceuticals AUPH Stock Holding History

K2 Principal Fund’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-58,772
Closed -$442K – 252
2022
Q3 		$442K Buy
+58,772
New +$509K 0.05% 153
2022
Q2 		– Sell
-47,462
Closed -$588K – 356
2022
Q1 		$588K Buy
+47,462
New +$734K 0.05% 159
2021
Q3 		– Sell
-139,499
Closed -$1.81M – 317
2021
Q2 		$1.81M Buy
+139,499
New +$1.78M 0.15% 183
2017
Q1 		– Sell
-201,522
Closed -$423K – 298
2016
Q4 		$423K Buy
+201,522
New +$648K 0.04% 211

Other funds holding AUPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

K2 Principal Fund's AUPH Position: Q4 2022 in Review

K2 Principal Fund sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2022, closing a stake of 58,772 shares — an estimated $442K sold.

K2 Principal Fund first reported a position in AUPH in Q4 2016 and held it in 4 quarters. The position peaked at $1.81M in Q2 2021. 192 funds tracked by Wall St. Rank hold AUPH as of Q4 2022.

  • K2 Principal Fund reported no remaining Aurinia Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • K2 Principal Fund sold 58,772 Aurinia Pharmaceuticals shares in Q4 2022, an estimated $442K.
  • K2 Principal Fund first reported a position in Aurinia Pharmaceuticals in Q4 2016 and held it in 4 quarters.
  • K2 Principal Fund's Aurinia Pharmaceuticals position peaked at $1.81M in Q2 2021.
  • 192 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2022.

Based on K2 Principal Fund's 13F filing for Q4 2022, filed 10 Feb 2023.